A Phase 2 interventional study of Denosumab and Calcium/Vitamin D in GCT and Giant Cell Tumor of Bone, sponsored by Amgen. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-11-08.
Sponsored by Amgen · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
To determine how safe and effective denosumab is in treating patients with giant cell tumor of bone.
23 studies on the registry are indexed under Giant Cell Tumor of Bone; 7 are open to participants now.
This study's enrollment of 37 is below the median of 43 across 16 interventional studies indexed under Giant Cell Tumor of Bone.
Browse Giant Cell Tumor of Bone studies →Amgen is the lead sponsor of 1,047 studies on the registry; 51 are open to participants now.
Of its 246 completed or terminated interventional studies of FDA-regulated products, 166 (67%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Other criteria also apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received denosumab 120 mg once every 4 weeks (Q4W), with an additional 120 mg doses on Days 8 and 15 of the first month of treatment. All participants were instructed to take daily supplements of at least 500 mg of calcium and 400 IU of vitamin D. Participants were to continue to receive denosumab until one of the following occurred: complete tumor resection, disease progression without clinical benefit, or decision by the participant to discontinue for any reason.
Biological: Denosumab · Dietary Supplement: Calcium/Vitamin D
Percentage of Participants With Giant Cell Tumor Response
A treatment response was defined for participants with tissue samples obtained and measured by histopathology as: • at least 90% elimination of giant cells relative to Baseline, or • complete elimination of giant cells in cases where giant cells represent \< 5% of tumor cells. A response was defined for participants who have only radiographs (histopathology not available) as lack of progression of the target lesion at week 25 by radiographic measurements compared with Baseline. For participants with both a core biopsy and resected tissue obtained, the sample closest to week 25 was used in the analysis.
Time frame: From enrollment until 25 weeks
Percent Change From Baseline in Urinary N-telopeptide Corrected for Urine Creatinine
Urinary N-telopeptide (of type 1 collagen) corrected for urine creatinine (uNTX/Cr) is a bone turnover marker used to measure the activity of denosumab. Percent change from Baseline in uNTX/Cr was measured over time.
Time frame: Baseline and Weeks 5, 9, 13, 17, 21, 25, 29, 33, 37, 41, 45, 49, 53, 57, 61, 65, 69, 73, 77, and 81
Percent Change From Baseline in Serum C-terminus Peptide (of Type 1 Collagen)
Serum C-terminus peptide (of type 1 collagen; CTX1) is a bone turnover marker used to measure the activity of denosumab. Percent change from Baseline in CTX was measured over time.
Time frame: Baseline and Weeks 5, 9, 13, 17, 21, 25, 29, 33, 37, 41, 45, 49, 53, 57, 61, 65, 69, 73, 77, and 81
Serum Denosumab Trough Concentrations
Serum concentrations of denosumab were measured by a validated conventional sandwich enzyme-linked immunosorbent assay (ELISA).
Time frame: Blood samples were collected on Days 1 (baseline), 8, 15 and Weeks 5 (Day 29), 9, 13, 25, and 49.
Number of Participants With Adverse Events (AEs)
An adverse event is defined as an undesirable medical occurrence (e.g., sign, symptom, or diagnosis) or worsening of a pre-existing medical condition. A serious adverse event (SAE) is defined by regulatory authorities as one that • is fatal • is life threatening (places the participant at immediate risk of death) • requires in-patient hospitalization or prolongation of existing hospitalization • results in persistent or significant disability/incapacity • is a congenital anomaly/birth defect • other significant medical hazard. The severity of adverse events was assessed according to the Common Terminology Criteria for Adverse Events (CTCAE, version 3.0) based on the following general guideline: Grade 1: Mild AE Grade 2: Moderate AE Grade 3: Severe AE Grade 4: Life-threatening or disabling AE Grade 5: Death related to AE. AEs were assessed by the Investigator for relatedness to study drug.
Time frame: From the first dose of study drug until the data cut-off date of April 7 2008; a maximum of 18 months
Number of Participants With Anti-Denosumab Antibodies
Validated immunoassays were used to test for the presence of anti-denosumab antibodies throughout the study.
Time frame: From enrollment until the data cut-off date of April 7 2008; a maximum time of 18 months.
First patient enrolled 10 July 2006; Last patient enrolled 25 January 2008. Results data are reported as of the data cut-off date of 07 April 2008.
| Milestone | Denosumab |
|---|---|
| Started | 37 |
| Completed | 7 |
| Not completed | 30 |
| Withdrew: Ongoing in study | 26 |
| Withdrew: Disease progression | 2 |
| Withdrew: Withdrawal by subject | 1 |
| Withdrew: Physician decision | 1 |
A treatment response was defined for participants with tissue samples obtained and measured by histopathology as: • at least 90% elimination of giant cells relative to Baseline, or • complete elimination of giant cells in cases where giant cells represent \< 5% of tumor cells. A response was defined for participants who have only radiographs (histopathology not available) as lack of progression of the target lesion at week 25 by radiographic measurements compared with Baseline. For participants with both a core biopsy and resected tissue obtained, the sample closest to week 25 was used in the analysis.
| percentage of participants | Denosumab |
|---|---|
| Percentage of Participants With Giant Cell Tumor Response | 85.7 (69.7 to 95.2) |
Urinary N-telopeptide (of type 1 collagen) corrected for urine creatinine (uNTX/Cr) is a bone turnover marker used to measure the activity of denosumab. Percent change from Baseline in uNTX/Cr was measured over time.
| percent change | Denosumab |
|---|---|
| Week 5 (n=30) | -70.9 (-79.6 to -15.0) |
| Week 9 (n=29) | -77.0 (-85.7 to -42.9) |
| Week 13 (n=27) | -60.0 (-84.2 to -36.0) |
| Week 17 (n=26) | -59.5 (-79.3 to -37.1) |
| Week 21 (n=24) | -64.5 (-80.1 to -19.1) |
| Week 25 (n=20) | -56.4 (-76.2 to 3.6) |
| Week 29 (n=21) | -52.8 (-78.4 to -22.8) |
| Week 33 (n=15) | -35.0 (-83.8 to 22.0) |
| Week 37 (n=13) | -71.1 (-83.4 to -41.4) |
| Week 41 (n=11) | -57.3 (-78.1 to -22.4) |
| Week 45 (n=8) | -59.1 (-81.8 to -47.5) |
| Week 49 (n=7) | -59.0 (-74.0 to -0.9) |
| Week 53 (N=8) | -49.0 (-81.5 to -29.3) |
| Week 57 (n=6) | -65.1 (-78.4 to -21.9) |
| Week 61 (n=3) | -59.2 (-92.5 to 23.1) |
| Week 65 (n=3) | -69.2 (-79.6 to 33.2) |
| Week 69 (n=4) | -64.2 (-88.8 to -13.4) |
| Week 73 (n=1) | -47.5 (-47.5 to -47.5) |
| Week 77 (n=2) | -76.8 (-86.8 to -66.7) |
| Week 81 (n=2) | -13.3 (-53.8 to 27.1) |
Serum C-terminus peptide (of type 1 collagen; CTX1) is a bone turnover marker used to measure the activity of denosumab. Percent change from Baseline in CTX was measured over time.
| percent change | Denosumab |
|---|---|
| Week 5 (n=33) | -78.9 (-85.2 to -71.2) |
| Week 9 (n=33) | -79.8 (-87.9 to -66.1) |
| Week 13 (n=31) | -80.4 (-85.7 to -71.3) |
| Week 17 (n=28) | -82.6 (-85.2 to -70.4) |
| Week 21 (n=26) | -82.0 (-87.0 to -66.4) |
| Week 25 (n=24) | -79.5 (-86.5 to -69.2) |
| Week 29 (n=21) | -82.8 (-85.2 to -60.3) |
| Week 33 (n=16) | -74.8 (-83.2 to -59.0) |
| Week 37 (n=14) | -82.4 (-87.0 to -69.6) |
| Week 41 (n=10) | -86.1 (-89.6 to -58.5) |
| Week 45 (n=8) | -79.6 (-86.4 to -70.0) |
| Week 49 (n=7) | -82.0 (-90.0 to -76.7) |
| Week 53 (N=8) | -87.3 (-89.8 to -84.2) |
| Week 57 (n=6) | -86.2 (-87.7 to -85.2) |
| Week 61 (n=4) | -84.9 (-88.3 to -83.0) |
| Week 65 (n=3) | -83.5 (-87.0 to -77.5) |
| Week 69 (n=4) | -84.2 (-86.9 to -80.0) |
| Week 73 (n=2) | -81.9 (-85.2 to -78.5) |
| Week 77 (n=2) | -84.2 (-87.5 to -80.9) |
| Week 81 (n=2) | -84.9 (-89.6 to -80.3) |
Serum concentrations of denosumab were measured by a validated conventional sandwich enzyme-linked immunosorbent assay (ELISA).
| ng/mL | Denosumab |
|---|---|
| Day 1 (n=32) | NA ± NA |
| Day 8 (n=32) | 19000 ± 24100 |
| Day 15 (n=28) | 31600 ± 27300 |
| Day 29 (n=33) | 36400 ± 20600 |
| Week 9 (n=32) | 27500 ± 17300 |
| Week 13 (n=25) | 23300 ± 12400 |
| Week 25 (n=23) | 19900 ± 9700 |
| Week 49 (n=9) | 21400 ± 8900 |
An adverse event is defined as an undesirable medical occurrence (e.g., sign, symptom, or diagnosis) or worsening of a pre-existing medical condition. A serious adverse event (SAE) is defined by regulatory authorities as one that • is fatal • is life threatening (places the participant at immediate risk of death) • requires in-patient hospitalization or prolongation of existing hospitalization • results in persistent or significant disability/incapacity • is a congenital anomaly/birth defect • other significant medical hazard. The severity of adverse events was assessed according to the Common Terminology Criteria for Adverse Events (CTCAE, version 3.0) based on the following general guideline: Grade 1: Mild AE Grade 2: Moderate AE Grade 3: Severe AE Grade 4: Life-threatening or disabling AE Grade 5: Death related to AE. AEs were assessed by the Investigator for relatedness to study drug.
| participants | Denosumab |
|---|---|
| Any AE | 33 |
| Serious AE | 5 |
| Fatal AE | 1 |
| AE leading to study discontinuation | 2 |
| AE leading to study drug discontinuation | 3 |
| CTCAE Grade 3, 4, or 5 | 5 |
| Any AE related to study drug | 10 |
Validated immunoassays were used to test for the presence of anti-denosumab antibodies throughout the study.
| participants | Denosumab |
|---|---|
| Number of Participants With Anti-Denosumab Antibodies | 0 |
Collected over up to 1 year 6 months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Denosumab 120 mg Q4W | — | 5/37 (13.5%) | 25/37 (67.6%) |
| Event | Denosumab 120 mg Q4W |
|---|---|
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 2/37 |
| NauseaGastrointestinal disorders | 1/37 |
| Lower respiratory tract infectionInfections and infestations | 1/37 |
| PneumoniaInfections and infestations | 1/37 |
| Ankle fractureInjury, poisoning and procedural complications | 1/37 |
| Back painMusculoskeletal and connective tissue disorders | 1/37 |
| Metastases to lungNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/37 |
| DepressionPsychiatric disorders | 1/37 |
| Acute respiratory distress syndromeRespiratory, thoracic and mediastinal disorders | 1/37 |
| Event | Denosumab 120 mg Q4W |
|---|---|
| Pain in extremityMusculoskeletal and connective tissue disorders | 7/37 |
| Back painMusculoskeletal and connective tissue disorders | 4/37 |
| HeadacheNervous system disorders | 4/37 |
| DiarrhoeaGastrointestinal disorders | 3/37 |
| FatigueGeneral disorders | 3/37 |
| NasopharyngitisInfections and infestations | 3/37 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 3/37 |
| ConstipationGastrointestinal disorders | 2/37 |
| NauseaGastrointestinal disorders | 2/37 |
| AstheniaGeneral disorders | 2/37 |
| Age, Continuous(years) | Denosumab |
|---|---|
| Mean | 33.9 ± 12.3 |
| Sex: Female, Male(Participants) | Denosumab |
|---|---|
| Female | 20 |
| Male | 17 |
| Race/Ethnicity, Customized(participants) | Denosumab |
|---|---|
| White or Caucasian | 27 |
| Black or African American | 2 |
| Hispanic or Latino | 5 |
| Asian | 3 |
| Giant Cell Tumor Disease Type(participants) | Denosumab |
|---|---|
| Primary unresectable | 13 |
| Recurrent unresectable | 18 |
| Recurrent resectable | 6 |
| Eastern Cooperative Oncology Group (ECOG) Performance Status(participants) | Denosumab |
|---|---|
| 0 - Fully Active | 13 |
| 1 - Restricted but ambulatory | 21 |
| 2 - Ambulatory but unable to work | 1 |
| 3 - Limited selfcare, confined to bed >50% daytime | 0 |
| 4 - Completely disabled | 0 |
| Missing | 2 |
| Percent of giant cells in tumor on pre-treatment biopsy(percentage of giant cells in tumor) | Denosumab |
|---|---|
| Mean | 28.7 ± 16.1 |
| Location of target lesion(participants) | Denosumab |
|---|---|
| Lower extremities | 8 |
| Upper extremities | 5 |
| Pelvis | 9 |
| Spine | 3 |
| Pulmonary disease | 9 |
| Dorsal vertebrae | 1 |
| Pelvic region | 1 |
| Missing | 1 |
No study locations are listed for this record.
Ran from Jul 2006 to primary completion in Apr 2008, 20 months.
Results were first posted in Mar 2014, 5 years 10 months after primary completion. A results delay was requested in Jun 2010.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Denosumab